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Abstract
Purpose: Previous published data showed an impact of single-nucleotide polymor-
phisms in the VEGF A and VEGFR2 genes on the survival of patients with various 
malignancies, among others diffuse large B-cell lymphoma (DLBCL).
Patients and Methods: We investigated the role of four VEGF-A and two VEGFR-2 
gene polymorphisms on the outcome of 273 patients with diffuse large B-cell lym-
phoma who were treated with R-CHOP within a prospective, randomized trial of the 
German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). The genomic 
DNA samples were analyzed using commercial DNA Probes (Applied Biosystems, 
USA) to detect single-nucleotide polymorphisms in the VEGF A rs699947, rs1570360, 
rs2010963, rs3025039 and rs1870377, and rs2305948 in the VEGFR2 receptor. 
Hundred healthy blood donors served as a control.
Results: There was no difference between the SNP allele frequencies in lymphoma 
patients compared to the control group for all investigated SNPs. None of the in-
vestigated SNPs was significantly associated with EFS or OS. After adjusting for the 
International Prognostic Index risk factors in a multivariate analysis, these results 
could be confirmed.
Conclusion: Single-nucleotide polymorphisms of the VEGF and VEGFR2 were not 
associated with a worse outcome in Caucasian patients with DLBCL.
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1  | INTRODUC TION
Diffuse large B-cell lymphoma (DLBCL) is the most common non-
Hodgkin's lymphoma. The addition of the CD20 antibody rituximab 
to conventional chemotherapy has substantially improved the out-
come of these patients in the last 15 years and is now the standard 
of care.1-5 Despite this improvement, more than 30% of patients 
with DLBCL will ultimately relapse and are in need for a salvage 
treatment.6 The International Prognostic Index (IPI), which was in-
troduced in 1993,7 is still the standard clinical tool to predict out-
comes in patients with aggressive lymphomas.8 Nevertheless, there 
is a constant pursuit of new prognostic markers, for example, ABC 
and GCB,9 vitamin D,10 or Fc-gamma receptor.11 Angiogenesis is of 
utmost importance in the progression of many malignancies. The 
vascular endothelial growth factor (VEGF) is known as a regulator 
of endothelial cell proliferation and plays a major role in angiogen-
esis.12 Furthermore, single-nucleotide polymorphisms (SNP) of the 
VEGF pathway have been associated with incidence and prognosis 
of many solid and hematologic malignancies,13,14 and the inhibition 
of angiogenesis pathways for example by VEGF antibodies or tyros-
ine kinase inhibitors has shown clinical benefit in colon 15 and kid-
ney cancer.16,17 In addition, VEGF and its cellular receptor, and the 
vascular endothelial growth factor receptor type 2 (VEGFR2) play a 
key role in leukemia-associated angiogenesis,18 and the VEGF gene 
(VEGFA) polymorphism was reported to predict the prognosis in pa-
tients with acute myeloid leukemia patients.19 Despite the success 
of VEGF antibodies for the treatment of solid tumors, it failed to 
prove its efficacy in hematologic neoplasias like DLBCL. Previously 
published studies showed no significant treatment effect of bevaci-
zumab whether as a single agent in patients with relapsed, aggres-
sive non-Hodgkin lymphoma 20 or in combination with R-CHOP as 
first-line treatment for patients with aggressive B-cell lymphoma.21 
There have been several reports in the literature22-24 that in aggres-
sive lymphoma, in particular in DLBCL, high VEGF serum levels, and 
elevated expression of VEGF in tissue biopsies are associated with a 
higher tumor burden and inferior overall survival (OS). Kim et al ob-
served in a Korean population of lymphoma patients that the VEGF-
receptor 2 polymorphism rs1870377 major allele TT had an inferior 
prognosis. It was hypothesized that the inferior binding of minor 
allele AA to VEGF impaired lymphoma angiogenesis and conferred 
the benefit.25 Therefore, the aim of this study was to investigate the 
effects of VEGF and VEGF-receptor polymorphisms on the progno-
sis of Caucasian patients with aggressive B-cell lymphoma treated 
with R-CHOP protocol within the prospective RICOVER-60 trial 
of the German High-Grade Non-Hodgkin Lymphoma Study Group 
(DSHNHL).
2  | MATERIAL S,  METHODS AND PATIENTS
In the RICOVER-60 trial of the DSHNHL, 1222 patients aged 
61-80 years with aggressive B-cell lymphoma were recruited be-
tween July 2000 and June 2005 by 203 institutions. The patients 
were randomized to 6 or 8 cycles of CHOP-14 (cyclophosphamide, 
vincristine, doxorubicin, and prednisone) with and without eight cy-
cles of rituximab in a 2 × 2 factorial design. The study was performed 
in accordance with the Declaration of Helsinki. All protocols had been 
approved by the ethics committee of each participating institution, 
and all patients had given written informed consent.5 From these 
1222 patients, 533 genomic DNA samples were available for further 
analysis. From these 533 patients, 273 received rituximab and were 
included in the final analysis. Patients with primary central nervous 
system lymphoma (PCNSL) and post-transplantation lymphoprolif-
erative disorders (PTLD) were excluded in the RIVOCER-60 trial and 
therefore not included in our analysis. The DNA samples were ana-
lyzed using commercial DNA Probes (Applied Biosystems, USA) to 
detect single-nucleotide polymorphisms in the VEGF A- (rs699947, 
rs1570360, rs2010963, and rs3025039) and in the VEGFR2 recep-
tor (rs1870377 and rs2305948). Minor allele frequencies were com-
pared with a control cohort of 100 healthy blood donors.
2.1 | Statistics
Event-free survival (EFS) was defined as time from randomization 
to disease progression, start of salvage treatment, additional (un-
planned) treatments, relapse, or death from any cause. Overall sur-
vival (OS) was defined as time from randomization to death from 
any cause. EFS and OS according to SNPs were estimated according 
to the Kaplan-Meier method, and global log-rank tests were per-
formed. Cox regression models to analyze the SNPs adjusted for the 
factors of the IPI were used for EFS and OS. Hazard ratios (HRs) 
with 95% confidence intervals (CI) and P-values are presented. For 
differences regarding patient characteristics, we used chi-square 
tests and for age the Mann-Whitney U test. The two-sided signifi-
cance level was P < .05. Haplotype analysis was performed for SNPs 
with high linkage disequilibrium. Individual haplotypes were inferred 
using the PHASE program (available at http://steph enslab.uchic ago.
Novelty Statements
1. What is the NEW aspect of your work?
VEGF polymorphisms in Caucasian patients with aggres-
sive B-cell lymphoma.
2. What is the CENTRAL finding of your work?
We investigated the prognostic impact of six potentially 
functional polymorphisms in the VEGF and VEGFR2 genes 
in Caucasian patients with aggressive B-cell lymphoma.
3. What is (or could be) the SPECIFIC clinical relevance of 
your work?
VEGF polymorphisms do not have a prognostic value 
in Caucasian patients with diffuse aggressive B-cell 
lymphoma.
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edu/phase/ downl oad.html). Statistical analysis was performed using 
SPSS software (version 11.5) and R (version 3.6.3).
3  | RESULTS
The characteristics of the 273 patients included in this study are 
shown in Table 1. This cohort did not significantly differ from the en-
tire RICOVER-60 population (n = 1222) with respect to demograph-
ics and IPI risk factors.
SNP allele frequencies were not different in lymphoma patients 
compared to healthy controls (data not shown). In univariate analy-
sis, no significant impact of the SNPs on EFS and OS was observed 
(Figure S1). Similarly, a multivariate analysis for EFS and OS adjusted 
for the factors of the IPI showed no impact of VEGF and VEGF-
receptor polymorphisms on prognosis of this series of patients with 
aggressive B-cell lymphoma (Table 2).
The three neighboring VEGFA SNPs rs699947, rs1570360, 
and rs2010963 were closely linked with each other but not with 
the VEGFA SNP rs3025039 (Table S1). VEGFR rs1870377 and 
rs2305948 polymorphisms were moderately linked (r2 = .078, 
Lewontin's D′ = 0.524). Four haplotypes of the gene VEGFA for 
alleles rs699947, rs1570360 and rs2010963 were estimated and 
considered for further analysis: AAG (34.2%), CGC (31.1%), AGG 
(16.7%), and CGG (17.8%) (AAC was not analyzed, because only one 
its copy was inferred in one patient). None of the haplotypes was 
significantly associated with EFS, which was the primary endpoint of 
the RICOVER-60 trial. Only the haplotype CGG was significantly as-
sociated with OS in a univariate analysis (P = .034) as well as adjust-
ing for IPI factors (haplotype copy number 1 (n = 79) vs. 0 (n = 181), 
HR, 0.5; 95% CI, 0.2-0.9; P = .019; Figure S2, Table S2). However, this 
association would no longer be significant, if multiple testing was 
taken into account.
4  | DISCUSSION
We have investigated the prognostic impact of six potentially func-
tional polymorphisms in the VEGF and VEGFR2 genes in Caucasian 
patients with aggressive B-cell lymphoma who were treated with 
R-CHOP. We could not find any impact of these polymorphisms on 
prognosis within these uniformly treated patients with aggressive 
B-cell lymphoma. Similarly, to certain solid malignancies for example 
ovarian 26 or head and neck cancers,27 VEGF polymorphisms do not 
have any prognostic value in Caucasian patients with DLBCL.
This is in contrast to previously published data by Kim et al which 
showed a significant impact on OS and PFS for the polymorphism 
VEGFR2 rs1870377T > A. In this Korean cohort, which had a com-
parable IPI risk and had been uniformly treated with R-CHOP as well, 
the three-year PFS for AA was 76,7%, for TA 68,0% and TT 59,7%, 
the OS for AA was 81,6%, for TA 73,4% and for TT 63,7%. This was 
independent of the IPI score in a multivariate analysis.25 In our co-
hort the three-year EFS for AA was 53.8%, for TA 73.5% and TT 
71,6%, the overall survival for AA was 64.1%, for TA 82% and for 
TT 77%. Contrary to the expectation the AA genotype in our cohort 
had a trend to a worse OS compared to AT + TT. However, this poly-
morphism had no impact on EFS and OS in our multivariate analysis.
The other assessed polymorphism (VEGFA rs699947, rs2010963 
and rs3025039, and VEGFR2 rs2305948) by Kim et al did not show 
any significant impact on OS or PFS supporting our own results. The 
EFS and OS were in a similar range in both cohorts indicating similar 
IPI risk and treatment conformity.
A validation cohort was missing in the publication by Kim et al, 
which underlines the necessity of validation cohorts for confirma-
tion of prognostic factors in hematologic malignancies. However, 
we cannot exclude that ethnicity (Korean vs Caucasian) may play a 
role in these findings even though there is no evidence in the lit-
erature described yet. We therefore would encourage a validation 
of the results of Kim et al to clarify this point because according to 
our results VEGF polymorphism do not have a prognostic value for 
patients with DLBCL.









68 (61-80) 68 (61-80) .550
Male 147 (54%) 650 (53%)
Female 126 (46%) 572 (47%) .859
LDH ≤ N 146 (53%) 618 (51%)
LDH > N 127 (47%) 604 (49%) .307
Stages I, II 140 (51%) 603 (49%)
Stages III, IV 133 (49%) 619 (51%) .511
ECOG 0,1 239 (88%) 1046 (86%)
ECOG > 1 34 (12%) 176 (14%) .346
Extralymphatic sites > 1
No 223 (82%) 1006 (82%)
Yes 50 (18%) 216 (18%) .823
IPI score
1 96 (35%) 372 (30%)
2 67 (25%) 339 (28%)
3 64 (23%) 313 (26%)
4, 5 46 (17%) 198 (16%) .203
No bulk 168 (62%) 759 (62%)
Bulk 105 (38%) 463 (38%) .880
B-symptoms 
no
187 (68%) 823 (67%)
B-symptoms 
yes
86 (32%) 399 (33%) .699
6× CHOP-14 128 (47%) 613 (50%)
8× CHOP-14 145 (53%) 609 (50%) .246
aP-value for comparison of patients analyzed (n = 273) and not analyzed 
(n = 949) from RICOVER-60 trial. 
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Nevertheless, our study has some limitations. First, it is small 
sample size in comparison to the Korean cohort (n = 494 vs. n = 273) 
and the fact that only six SNPs were studied even though nowadays 
genome-wide association study offers the opportunity to analyze a 
large number of SNPs at the same time. Second, due to the design of 
the RICOVER-60 trial gene-expression profiling information about 
the cell of origin (COO) was not available in all patients, which did 
not allow us to correlate our findings with the COO. Earlier studies 
showed that this phenotypic distinction is associated with overall 
survival after R-CHOP chemotherapy.28 Nevertheless, an already 
published analysis including patients from the RICOVER-60 and 
other German trials showed no clinical impact of COO on patients 
with DLBCL.29 Furthermore, we were not able to correlate our find-
ings with soluble isoform of VEGF, which has been shown to be a pre-
dictor for outcome in patients with de novo DLBCL,30 or relapsed/
refractory DBLCL31—this should be addressed in future studies.
The strengths of our study are its collection of patient samples 
within a randomized controlled trial with uniform and well-docu-
mented treatment and clinical outcome data, which minimize a prob-
ably existing selection bias in previous published data addressing 
this issue.
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